New publication from Véronique Baud's group in Blood Advances
Plasma metabolomics enables improved risk stratification in diffuse large B-cell lymphoma
“Risk stratification of patients with diffuse large B-cell lymphoma using plasma NMR-based metabolomics at diagnosis” – Blood Advances, 2026
In the team “Cell Growth Control by Nutrients” directed by Mario Pende (INEM), the group led by Véronique Baud, recently established at INEM and focusing on the research axis “NF-κB, Metabolism, Immunity and Cancer”, reports new insights into patient stratification in diffuse large B-cell lymphoma (DLBCL).
In this study published in Blood Advances, Véronique Baud (last author) and colleagues explore the potential of plasma metabolomics at diagnosis to better identify high-risk patients. Using a retrospective cohort of 154 DLBCL patients treated with standard R-CHOP therapy (REMARC trial), the authors performed nuclear magnetic resonance (NMR)-based metabolomic analyses on plasma samples collected at diagnosis.
The study identifies a combination of three circulating metabolites linked to lipid metabolism - 2-aminobutyrate, 3-hydroxybutyrate and LDL-1 lipoprotein - which together define an “NMR score”. This score stratifies patients into low-, intermediate- and high-risk groups and is strongly associated with both overall survival and progression-free survival, independently of established molecular markers.
By revealing metabolic signatures predictive of patient outcome at diagnosis, this work highlights the potential of NMR-based metabolomics as a non-invasive tool to refine risk stratification in DLBCL. These findings open new perspectives for the early identification of patients who may benefit from alternative or intensified therapeutic strategies.
🔗 Click here to access the article
Image credits: Montagne A. et al., Blood Advances, 2026